CHRB Dismisses Bisphosphonate Complaint Against Jeff Metz

California Horse Racing Board commissioners (Board) voted during closed session Sept. 15 to dismiss a complaint against trainer Jeff Metz pertaining to a positive test last year for a bisphosphonate in one of the horses in his care, Camino de Estrella.

The Board believed it would be unfair to punish Metz when both testing and investigation revealed that the bisphosphonate administration occurred in 2018, well before Metz ever trained the horse.

The complaint (posted on the CHRB website since December) stated that the Maddy Laboratory at UC Davis detected Tiludronic Acid (Tildren, a bisphosphonate) in the urine sample taken from Camino de Estrella after he finished sixth in the third race at Santa Anita on Sept. 27, 2020. The presence of the Class 1 drug prompted the stewards at Del Mar to later disqualify Camino de Estrella and order the redistribution of the purse. The disqualification remains in force and is not affected by the dismissal of the complaint against Metz.

The Board dismissed the complaint pursuant to Business & Professions Code 19577 (d): “Any recommendation to the board by the executive director to dismiss the matter shall be by mutual agreement with the equine medical director. The authority for the disposition of the matter shall be the responsibility of the board.”

The post CHRB Dismisses Bisphosphonate Complaint Against Jeff Metz appeared first on Horse Racing News | Paulick Report.

Source of original post

California Horse Racing Board Issues Bisphosphonate Complaint Against Jeff Metz

The California Horse Racing Board issued a complaint against trainer Jeff Metz last week over a finding of bisphosphonates in the Sept. 27, 2020 post-race sample of the gelding Camino De Estrella, reports the Daily Racing Form. The drugs are not yet specifically classified in California, so the positive is being adjudicated under the “prohibited substances” rule with a Class 1, Category A penalty.

However, Metz's attorney Darrell Vienna believes the trainer will be exonerated. Popular at the claim box, Camino de Estrella has been in the care of five different trainers since 2019, including Tim Yakteen, Mark Glatt, Steve Knapp, Metz, and most recently Bill Spawr.

“There is a record of a veterinarian administering the drug when he was not in Mr. Metz's care, in 2019,” Vienna told DRF. “I can say with certainty that Jeff never administered bisphosphonates to that horse. We're confident that the truth will come out, because we think the CHRB already knows the truth.”

Bisphosphonates were approved for equine use in the United States approximately six years ago, to treat horses with symptoms of navicular syndrome, a common, nagging foot pain in older horses. Before the drugs were approved for horses in the U.S., they were used in Europe and veterinarians could legally import them to treat American horses. Having them available to American practitioners who perhaps couldn't previously afford the import process has made a world of difference to mature horses dealing with navicular syndrome – and there are a lot of them. Roughly a third of chronic front leg lamenesses are believed to be related to navicular pain. Generally, bisphosphonates have been safe and effective in the population they're intended for.

Bisphosphonates (sold commercially as Osphos and Tildren) are FDA-approved in horses four years old and up, and are not approved for use in mares who are pregnant or lactating. The reason for those restrictions is unanswered questions about potential side effects. Bisphosphonates do their work by reducing the action of cells called osteoclasts, which clear away damaged bone and make way for osteoblasts to lay down new bone. In a young equine skeleton, this could disrupt the growth cycle.

The CHRB did prohibit the administration of bisphosphonates beginning July 1, 2020, via rule 1867.1, which also prohibits any horse from entering CHRB grounds that has been administered the drug within six months.

Since Camino de Estrella would have been five years old in 2019, administration of a bisphosphonate was legal at that time only if the gelding had a diagnosis of navicular disease.

Vienna argued that “the available science on bisphosphonates clearly demonstrates that the drug can be found more than 2 1/2 years after the drugs have been administered, due to their unique ability to lie dormant in bone but become 'active' in the horse's circulatory system when bone is in need of repair.”

Read more at the Daily Racing Form.

The post California Horse Racing Board Issues Bisphosphonate Complaint Against Jeff Metz appeared first on Horse Racing News | Paulick Report.

Source of original post

Verified by MonsterInsights